Pharvaris (PHVS) Cash from Operations Growth (1y) (2021 - 2026)

Pharvaris (PHVS) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 4.87%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -28.96%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 75.58%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -119.28%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 100.14%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 151.70%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 56.79%
10 Pharvaris 2.29 Bn 1.92 Bn - -29.47%

Historic Data

Download Data
DateValue
Jun 30, 2026 -29.47%
Mar 31, 2026 -41.08%
Dec 31, 2025 -18.28%
Sep 30, 2025 1.85%
Jun 30, 2025 -13.84%
Mar 31, 2025 -53.73%
Dec 31, 2024 -45.81%
Sep 30, 2024 -100.00%
Jun 30, 2024 100.00%
Mar 31, 2024 2.69%
Dec 31, 2023 -23.00%
Sep 30, 2023 324,922,255.76%
Jun 30, 2023 -340,632,884.32%
Mar 31, 2023 -34.80%
Dec 31, 2022 -45.61%
Sep 30, 2022 -29.31%
Jun 30, 2022 -2.26%
Mar 31, 2022 -63.12%
Dec 31, 2021 -34.62%
Sep 30, 2021 -53.00%